Friday, September 20, 2019
    Latest

    Pharma Watch

    Home Pharma Watch
    Merck Receives FDA Breakthrough Therapy Designation for Tepotinib in Patients With Metastatic NSCLC With METex14 Skipping Alterations
    Pharma Watch

    Merck Receives FDA Breakthrough Therapy Designation for Tepotinib in Patients With...

    0
    Global Blood Therapeutics Announces FDA Acceptance of New Drug Application and Priority Review for Voxelotor for the Treatment of Sickle Cell Disease
    Pharma Watch

    Global Blood Therapeutics Announces FDA Acceptance of New Drug Application and...

    0
    FDA Approves Boehringer Ingelheim’s Ofev in Patients With Sclerosis-Associated Lung Disease
    Pharma Watch

    FDA Approves Boehringer Ingelheim’s Ofev in Patients With Sclerosis-Associated Lung Disease

    0
    United Therapeutics Announces FDA Accepts for Review an NDA for Trevyent for the Treatment of Pulmonary Arterial Hypertension`
    Pharma Watch

    United Therapeutics Announces FDA Accepts for Review an NDA for Trevyent...

    0
    Ra Pharmaceuticals Receives FDA Orphan Drug Designation for Zilucoplan for the Treatment of Myasthenia Gravis
    Pharma Watch

    Ra Pharmaceuticals Receives FDA Orphan Drug Designation for Zilucoplan for the...

    0
    OBI Pharma Announces U.S. FDA Clearance of IND for a Phase 12 Study of its Antibody-Drug Conjugate Targeted Cancer Therapy, OBI-999
    Pharma Watch

    OBI Pharma Announces U.S. FDA Clearance of IND for a Phase...

    0
    Magenta Therapeutics Receives FDA RMAT Designation for MGTA-456 for the Treatment of Inherited Metabolic Disorders
    Pharma Watch

    Magenta Therapeutics Receives FDA RMAT Designation for MGTA-456 for the Treatment...

    0
    Cape Breton Could Become an Important Place in the Attack on Pancreatic Cancer: Encyt Technologies Awaits Health Canada Approval
    Pharma Watch

    Cape Breton Could Become an Important Place in the Attack on...

    0
    San Francisco-Based, Infectious Disease-Focused Vir Biotechnology Now Files for IPO
    Pharma Watch

    San Francisco-Based, Infectious Disease-Focused Vir Biotechnology Now Files for IPO

    0
    doctor view output CT scan.
    Pharma Watch

    Viela Bio Announces FDA Accepts for Review a BLA for Inebilizumab...

    0
    123...12Page 1 of 12
    - Advertisement -

    EDITOR PICKS

    TrialSite News is the only digital media dedicated 100% to transparent and open coverage of clinical research trial sites around the globe. Based in the Silicon Slopes in downtown Salt Lake City, Utah, we are founded by a team of experts in the clinical trials industry and dedicated to transparency, quality and clinical trial innovation.

    159 West Broadway Suite 200
    Salt Lake City, UT 84101

    Contact us: admin@trialsitenews.com
    © TrialSite News, Inc. All Rights Reserved